Dermatology and TherapyIntroduction Despite advancements in the treatment of psoriasis (PsO), there are few head-to-head studies assessing comparative effectiveness of the newest therapies approved to treat PsO.
April W. Armstrong +5 more
doaj +2 more sources
Risankizumab in Severe Asthma: A Phase IIa, Placebo-Controlled Study [PDF]
, 2021 Background: Interleukin (IL)-23 is implicated in T2- and T17-mediated airway inflammation, supporting a role in asthma. Methods: We undertook a Phase II, randomized, double-blind, placebo-controlled, 24-week, parallel-group, multicenter trial to assess ...
Renaud Louis (394437) +16 more
core +2 more sources
Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study. [PDF]
, 2021 peer reviewedBACKGROUND AND AIMS: Risankizumab, an interleukin-23 antibody, demonstrated efficacy and acceptable safety in a phase 2 study of patients with moderate-to-severe refractory Crohn's disease.
Kaser, Arthur +45 more
core +1 more source
Risankizumab: Daily Practice Experience of High Need Patients [PDF]
, 2023 Psoriasis is a chronic inflammatory disease which affects 29.5 million people worldwide and it can negatively impact quality of life, especially when it affects a special localization, such as nails, face, palms and soles, or intertriginous regions ...
Caldarola G. +16 more
core +2 more sources
Risankizumab in Severe Asthma - A Phase 2a, Placebo-Controlled Trial
, 2021 BACKGROUNDInterleukin-23 has been implicated in airway inflammation that is mediated by type 2 and type 17 cytokines. Whether targeting interleukin-23 in the treatment of asthma improves disease control and reduces airway inflammation is unclear ...
Renaud Louis (394437) +4 more
core +4 more sources
A non-clinical comparative study of IL-23 antibodies in psoriasis
mAbs, 2021 Four antibodies that inhibit interleukin (IL)-23 are approved for the treatment of moderate-to-severe plaque psoriasis. Here, we present non-clinical data comparing ustekinumab, guselkumab, tildrakizumab and risankizumab with regard to thermostability ...
Li Zhou +19 more
doaj +1 more source
Peristomal Pyoderma Gangrenosum Responding to Risankizumab
, 2021 Evidence to support available therapies for pyoderma gangrenosum (PG) is limited. Many patients do not respond to topical therapies such as tacrolimus or topical steroids. Currently favored oral systemic treatments (eg, cyclosporine and steroids) achieve
Kirsner, Robert S +3 more
core +1 more source
Open-label extension of a phase 2 trial of risankizumab in patients with moderate-to-severe Crohn's disease [PDF]
, 2018 Background: Risankizumab, an anti-interleukin-23 antibody, was superior to placebo in achieving clinical and endoscopic remission at week 12 in a randomised, phase 2 induction study in patients with moderately to severely active Crohn’s disease.
core +2 more sources
, 2023 225231OBJECTIVE: To evaluate risankizumab, a biological therapy that inhibits interleukin 23, in patients with active psoriatic arthritis (PsA) who have responded inadequately or are intolerant to ≥1 conventional synthetic disease-modifying antirheumatic
Papp, K. +10 more
core +1 more source
Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil [PDF]
Anais Brasileiros de Dermatologia: Background: Psoriasis, a chronic, inflammatory skin disease, requires long-term therapy. Risankizumab is a humanized immunoglobulin G1 monoclonal antibody that specifically inhibits interleukin 23 by binding to its p19 subunit. Objective: The authors
Tania F. Cestari +16 more
doaj +1 more source